Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland

Andrea Favre-Bulle, Goran Bencina, Shujing Zhang, Ruixuan Jiang, Daniel Andritschke & Arjun Bhadhuri
To assess the cost-effectiveness of adjuvant pembrolizumab versus observation for patients with resected stage IIB/IIC melanoma from a third-party payers’ perspective in Switzerland over a lifetime horizon. A Markov state transition model with four health states (recurrence-free [RF], locoregional recurrence, distant metastases [DM], and death) was developed to determine the cost-effectiveness of pembrolizumab versus observation as an adjuvant treatment in patients with stage IIB/IIC melanoma who have undergone complete resection. The model utilized data from...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.